Breaking News Instant updates and real-time market news.

NVAX

Novavax

$1.88

0.08 (4.44%)

08:55
10/11/16
10/11
08:55
10/11/16
08:55

Novavax to hold analyst and investor meeting

Analyst and Investor Meeting is being held in New York on October 11 at 9 am. Webcast Link

  • 11

    Oct

  • 09

    Nov

NVAX Novavax
$1.88

0.08 (4.44%)

09/16/16
09/16/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. 21st Century Fox (FOX, FOXA) downgraded to Market Perform from Outperform at Bernstein with analyst Jason Park citing a reduction in his estimates for the company's Star India business. 2. Wells Fargo (WFC) downgraded to Underweight from Neutral at Atlantic Equities. 3. Citi (C) downgraded to Neutral from Buy at Goldman with analyst Richard Ramsden saying Citi's expected earnings inflection has failed to materialize and ROEs are at 7.7%, well below management's 10% target. 4. McCormick (MKC) downgraded to Market Perform from Outperform at Bernstein with analyst Alexia Howard citing valuation. 5. Novavax (NVAX) downgraded to Neutral from Overweight at Piper Jaffray, to Neutral from Overweight at JPMorgan, to Neutral from Buy at Ladenburg, to Neutral from Outperform at Wedbush, and to Neutral from Buy at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/16/16
SBSH
09/16/16
DOWNGRADE
Target $1.5
SBSH
Neutral
Novavax downgraded to Neutral from Buy at Citi
Citi analyst Joel Beatty downgraded Novavax to Neutral after the company's RSV vaccine for older adults failed in Phase 3. The analyst does not expect results from the one remaining clinical trial until 2019. He cut his price target for the shares to $1.50 from $12. Four other firms downgraded Novavax this morning.
09/16/16
WEDB
09/16/16
DOWNGRADE
Target $2
WEDB
Neutral
Novavax downgraded to Neutral from Outperform at Wedbush
Wedbush analyst Heather Behanna downgraded Novavax to Neutral and lowered its price target to $2 from $14 after the company's Phase III trial of RSV vaccine failed. This is the fourth downgrade of Novavax today.
09/16/16
LTCO
09/16/16
DOWNGRADE
LTCO
Neutral
Novavax downgraded to Neutral from Buy at Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter downgraded Novavax to Neutral without a price target after the company's Phase III trial for the RSV F nanoparticle vaccine failed. Shares were also downgraded this morning at Piper Jaffray and JPMorgan.

TODAY'S FREE FLY STORIES

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

, BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

17:43
04/23/17
04/23
17:43
04/23/17
17:43
Earnings
C.R. Bard sees Q2 adjusted EPS $2.75-$2.85, consensus $2.87 »

Sees Q2 revenue growth…

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

, BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

17:41
04/23/17
04/23
17:41
04/23/17
17:41
Earnings
C.R. Bard reports Q1 adjusted EPS $2.87, consensus $2.65 »

Reports Q1 revenue…

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:38
04/23/17
04/23
17:38
04/23/17
17:38
Hot Stocks
Becton Dickinson names Polen as president, says will lead Bard segment »

BD (BDX) announced the…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

HCMLY

LafargeHolcim

$11.56

-0.1 (-0.86%)

17:32
04/23/17
04/23
17:32
04/23/17
17:32
Periodicals
LafargeHolcim CEO set to step down, FT reports »

LafargeHolcim CEO Eric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:30
04/23/17
04/23
17:30
04/23/17
17:30
Hot Stocks
Becton Dickinson outlines strategic highlights of C.R. Bard acquisition »

Expanding on the…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

KLRE

KLR Energy Acquisition

$10.40

-0.02 (-0.19%)

17:29
04/23/17
04/23
17:29
04/23/17
17:29
Conference/Events
KLR Energy Acquisition to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:23
04/23/17
04/23
17:23
04/23/17
17:23
Hot Stocks
BD sees forming third business segment, says Bard CEO to join board »

Commenting on its…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:20
04/23/17
04/23
17:20
04/23/17
17:20
Hot Stocks
BD sees high single-digit EPS accretion in FY19 »

"This financially…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:18
04/23/17
04/23
17:18
04/23/17
17:18
Hot Stocks
Becton Dickinson says expects to continue buyback suspension »

"BD expects to…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:16
04/23/17
04/23
17:16
04/23/17
17:16
Hot Stocks
Becton Dickinson to acquire C.R. Bard in $24B cash and stock deal »

BD (BDX) and C. R. Bard…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:10
04/23/17
04/23
17:10
04/23/17
17:10
Hot Stocks
Breaking Hot Stocks news story on Becton Dickinson, C.R. Bard »

Becton Dickinson to…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

CS

Credit Suisse

$14.45

-0.09 (-0.62%)

17:07
04/23/17
04/23
17:07
04/23/17
17:07
Periodicals
Credit Suisse to determine capital raise plan after annual meeting, Reuters says »

Credit Suisse will make a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$142.27

-0.17 (-0.12%)

17:04
04/23/17
04/23
17:04
04/23/17
17:04
Periodicals
Uber CEO ordered iPhone tracking, was scolded by Tim Cook, NYT says »

Beginning in 2014, ride…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

AVID

Avid Technology

$5.11

0.19 (3.86%)

, MSFT

Microsoft

$66.40

0.9 (1.37%)

16:30
04/23/17
04/23
16:30
04/23/17
16:30
Hot Stocks
Avid announces strategic cloud alliance with Microsoft »

Avid (AVID) announced it…

AVID

Avid Technology

$5.11

0.19 (3.86%)

MSFT

Microsoft

$66.40

0.9 (1.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 09

    May

  • 09

    May

15:44
04/23/17
04/23
15:44
04/23/17
15:44
Conference/Events
Wolfe Research utilities analyst holds an analyst/industry conference call »

Utilities Analyst…

OA

Orbital ATK

$97.28

-0.65 (-0.66%)

15:32
04/23/17
04/23
15:32
04/23/17
15:32
Hot Stocks
Breaking Hot Stocks news story on Orbital ATK »

Orbital ATK says Cygnus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRV

ContraVir Pharmaceuticals

$1.41

-0.09 (-6.00%)

15:30
04/23/17
04/23
15:30
04/23/17
15:30
Hot Stocks
ContraVir presents data on hepatitis B candidates TXL, CRV431 »

ContraVir Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASPS

Altisource

$24.05

-1.39 (-5.46%)

, NRZ

New Residential

$16.34

-0.05 (-0.31%)

15:30
04/23/17
04/23
15:30
04/23/17
15:30
Conference/Events
Piper Jaffray specialty finance analyst holds analyst/industry conference call »

Regional Banks &…

ASPS

Altisource

$24.05

-1.39 (-5.46%)

NRZ

New Residential

$16.34

-0.05 (-0.31%)

OCN

Ocwen

$2.42

-0.07 (-2.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 03

    May

  • 24

    May

MRK

Merck

$61.89

-0.66 (-1.06%)

15:27
04/23/17
04/23
15:27
04/23/17
15:27
Hot Stocks
Merck reports new Phase 2 MK-3682B data »

Merck announced the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 07

    May

  • 10

    May

  • 27

    May

  • 09

    Jun

  • 14

    Jun

ABUS

Arbutus Biopharma

15:10
04/23/17
04/23
15:10
04/23/17
15:10
Hot Stocks
Arbutus reports ARB-1467 study data, plans additional trial in 2H »

Arbutus Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 26

    Apr

ACHN

Achillion

$3.64

-0.02 (-0.55%)

, JNJ

Johnson & Johnson

$121.76

-0.11 (-0.09%)

15:05
04/23/17
04/23
15:05
04/23/17
15:05
Hot Stocks
Achillion reports updated data from Phase 2 JNJ-4178 study »

Achillion Pharmaceuticals…

ACHN

Achillion

$3.64

-0.02 (-0.55%)

JNJ

Johnson & Johnson

$121.76

-0.11 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 06

    Jun

BMY

Bristol-Myers

$53.48

0.04 (0.07%)

14:59
04/23/17
04/23
14:59
04/23/17
14:59
Hot Stocks
Bristol-Myers says '036 NASH study meets primary endpoint »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 03

    May

  • 06

    Jun

14:52
04/23/17
04/23
14:52
04/23/17
14:52
General news
Breaking General news story  »

Fillon concedes as Le…

ALBO

Albireo Pharma

$20.66

-0.26 (-1.24%)

14:45
04/23/17
04/23
14:45
04/23/17
14:45
Hot Stocks
Albireo Pharma reports 'promising' A4250 data, sees Phase 3 trial start in 2H »

Albireo Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$88.62

-0.71 (-0.79%)

14:34
04/23/17
04/23
14:34
04/23/17
14:34
Hot Stocks
ShaveLogic says wins summary judgement over Gillette »

ShaveLogic issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.